Member Info for GlenFidrich

With an almost 20% stake in the company, it would seem Ashanti is confident. One reason to be invested anyway.

I'm not sure we were ever told that consolidation would eradicate volatility (or at least I can't find such a statement anywhere). For example, this from the Half-year Report: "Regarding the Consolidation, the Board is of the opinion that the high number of Existing Ordinary Shares (currently 3,403,470,791) and the low absolute share price negatively affect investors' perception of the Company and considers the Consolidation to be in the best interests of the Company and its shareholders." It was all to do with reducing the number of shares in issue and increasing the SP, so that we weren't perceived as some basket-case penny share. Volatility is a separate issue in my opinion. Actually, with only 68m shares in issue now we might well see wild swings, as the scarcity of shares will feed the buying frenzy (when it comes). Furthermore, with the geopolitical situation such as it is, volatility has been the order of the day and Sareum has borne the brunt, sadly. The volatility index (VIX) tells you everything you need to know about current volatility and recent market turmoil. It doesn't excuse today's shenanigans, however.

Reported here, of course, as a sell.

Just topped up at 1.12. Hopefully not too much more downside risk from here. GLA.

PUR and FRES I concur. You might look at GFM. When POG rebounds (on news of a ceasefire?), the potential upside could be enormous here.

I think a lot has been achieved by the recent consolidation. Most significantly, the number of shares in issue has been reduced from 3.4 billion to 68 million. We now have a similar number of shares in issue as NCYT, and coincidentally a similar market cap., and we all know how rapidly NCYT's share price increased last year. I think the main reason for that rise was the scarcity of available shares, and I think we might find the same sort of rise is possible with SAR, especially given the fairly large number of LTHs who are unwilling to sell they shares too cheaply. In essence, our golden tickets have just become 50x more scarce. In addition, SAR can no longer be perceived as a penny share, and therefore may well be taken more seriously by investors/institutions with deep pockets. We know that the science is compelling. We just need to convince the large investment houses to come on board, and through the consolidation I believe we have taken a giant step towards achieving that aim.

Ditto re: II. No problems here.

The tweet: "Looking forward to meeting @Sareumplc shareholders again at today's EGM. Approval of the share consolidation will signal the start of a new Sareum!"
(1) Not sure he'd be "looking forward" to meeting us if he thought we might be a lynch mob, demanding answers re: the whys and wherefores of consolidation, the wisdom of appointing PH, and generally baying for blood? The result is a foregone conclusion, and SP knows it (as do most of us, if we're honest).
(2) The use of the future tense - "will signal" - suggests to me that he's confident of the future of Sareum, post-consolidation. But - and here's the rub - if you vote against? What then? The 'old' Sareum wasn't so bad, surely? Unless he means by 'new Sareum' that we have a buyer in the wings, conditional on consolidation being approved, and everyone is going to be as rich as Croesus? This is version of consolidation I like!

LeMajor, I was kind of hoping/thinking the same. 4p by close of play Monday would mean 2GBP open on Tuesday. But I'm expecting a temporary drop post-consolidation, maybe to the tune of 10%? Thereafter, I think the SP will rise, possibly to around 4GBP, at which point I'll probably bail. I'm basing a lot of my predictions on my OXB experience, which has followed a similar pattern. Each to their own, and GLA.

Forgive my ignorance, but I thought our last day as a penny share was Monday, 28th February?

It's hardly a wholesale exodus with roughly 9m shares traded so far. That being said, I'm never quite sure of the volumes as reported here, but even if it was double that (i.e. 18m shares traded), that represents what, roughly 0.6% of shares in issue. Really see this as a massive buying opportunity ahead of Monday. But the fear/volatility indices are no doubt through the roof. Each to their own, I guess. GLA, and prayers for peace.

Siennaj, as share4 referred to, there is a new strain of the Omicron variant (named BA.2) that is as virulent but with more severe symptoms, especially amongst the unvaccinated. Chris Whitty (love him or hate him!) also came out recently to say the government's decision to remove all restrictions was premature. In countries like China (Hong Kong), and Thailand, cases are again out of control, so gut feeling is further disruption is inevitable, which sadly may impact the likes of PYC. Just my opinion, but I think explains PYC's disappointing SP. Riddler will no doubt shoot me down and consign me to the filter box. A badge of honour, actually!!

Riddler, yep, have been keeping abreast of news here, such as it is.
I'm glad you're declaring Covid over. You are aware of the new variants of concern coming to the fore? Moreover, as recently as 30th September, 2021, reference was made by PYC to "COVID related headwinds". Indeed, "the ongoing COVID 19 crisis has led to a delay in the commencement of our NIHR funded trial at the Portsmouth Technology Trials Unit although the Company was pleased to receive ethics committee and UK Health Research Authority approval for the trial in December 2020 and the trial formally opened in August 2021. It is expected to last around one year(!). In addition, a number of the Company's current and potential new clients saw delays in the commencement or recruitment to their own clinical trials, which have had a knock-on effect due to associated delays in the generation of data needed for modelling(!). We believe, however, that for the most part these will be timing issues leading to delays(!) rather than cancellations of projects." I, for one, have indeed been reading the news. Perhaps you might deign to do likewise.
Berkshire hunt.
P.S. How's your DMTR recommendation doing? Oh, wait, most shareholders are down 90%. You might want to explain your pumping of that share to them? Just a thought...

Looks like he's jumping ship. Can't be good news, imho. 4.85p a new 52-week low, I think. I had high hopes for PYC - still have - but Covid-related delays have really hit us hard. At these levels, this must be a screaming buy? Anyone?

Appreciate all the informative posts, citizen (and all others). When I can, if someone poses a question, I try to answer positively, helpfully. Occasionally, I post links to articles. I just think the science side is often above my pay grade and so I appreciate people explaining it simply. Apologies if my understanding of the science is rather basic for some here. But when asking a question, it would be helpful if we all tried to answer politely, myself included. Let's leave it at that!

When you tried to belittle me for simply asking a question ("Jeez some people!"). Don't be an ******* all your life, there's a good chap.

Thanks, citizen, for the clarification. The science has always kind of baffled me although I do try to get my head around it! Obviously, sad old twat thinks to be invested here we should all have degrees in biochemistry!

Sorry to be thick about this, but is this good news or bad news for SRA737? "Genomic instability" and "synthetic lethality" sounds worrisome (not to mention "Discontinued"), but are you suggesting it's one less Chk1 inhibitor for SRRA with which to compete (and therefore good news)? In the article you cite, it states: "The Chk1 inhibitor (AZD7762) tested showed good synergism with standard-of-care myeloma drugs, velcade and melphalan, thus further reinforcing the translational potential of this therapeutic approach." This also sounds promising, surely? As I say, maybe I'm missing something obvious but I'm still confused.

No suspension, as per the following RNS:
https://www.lse.co.uk/rns/SAR/publication-of-circular-notice-of-general-meeting-xx3l0n3j1m9dfta.html
"Record Date and completion of Consolidation 6.00 p.m. on 28 February 2022
Expected date on which New Ordinary Shares will be admitted to trading on AIM 8.00 a.m. on 1 March 2022".

Excellent riposte, Ahfam, and a compelling argument for topping up at these levels.